



OptumRx Programs

BriovaRx Smart Fill Program Overview

	Split Fill (1/2 Monthly Supply)	90-Day Supply				
Conditions/Drugs	Oral Oncology	HIV, MS, RA, Transplant				
Patient Stability	Unstable on medication	Stable on medication				
Clinical Intent	Adjust to medication	Adherence				
Program Intent	Avoid waste	Member convenience				
Member Experience	Increased clinical oversight	Improved satisfaction				
# Fills/Duration	6 fills over first 3 months	4 fills over 12 months				
Copays	½ copay	3x copay				
Opt in	No (mandatory)	Yes (voluntary)				
Program Offering	Split Fill (1/2 Monthly Supply) only Impacts Newly Diagnosed 90 Day Supply, Must be adherent 6 months or more					



Targets new unique chemical entities and new drug products that fall within the scope of the pharmacy benefit that have yet to undergo review by the OptumRx Pharmacy &Therapeutics Committee.

- Temporary exclusion list for new drugs not immediately meeting criteria for placement on one of the other exclusion lists, or for drugs that are pending a decision for placement.
- After six months (or sooner), the drug will either be added to the formulary with any planned UM or added to one of the other exclusion lists



Ongoing Exclusion List for Drugs therapeutically similar to covered drugs but cost much more.

Combination Medications			"Unique" Strengths or Flavors		Different Delivery Device	
Combining tw available med make a ne	dications to	when 5m	g a	e" strength Ind 10mg available	Different delivery device, worth 5x more than Tier 1 generic?	
	"Unique" Dosage Forms			Multiple Pack	\mathbf{i}	
	Special cherry flavor = 21x more than Tier 1 generic			Two or more available medications (packaged together), often an OTC or generic		



What is it?

Ongoing Exclusion List that targets new drugs that are deemed non-essential treatments and are deemed out of scope for P&T review, including but not limited to:

Pain Patches and creams

Outrageously expensive topical pain preparations and "kits" made up of ingredients that are inexpensive when sold individually.

Drugs with no legitimate FDA indication and P&T out-of-scope products

High-dollar, non-FDA approved products as well as things like surgical supplies where they likely won't be covered via prescription benefit.



